Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PIPE-791 by Contineum Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
PIPE-791 is under clinical development by Contineum Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
PIPE-791 by Contineum Therapeutics for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
PIPE-791 is under clinical development by Contineum Therapeutics and currently in Phase I for Secondary Progressive Multiple Sclerosis (SPMS). According...
PIPE-791 by Contineum Therapeutics for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
PIPE-791 is under clinical development by Contineum Therapeutics and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS). According...
PIPE-791 by Contineum Therapeutics for Neuroinflammation: Likelihood of Approval
PIPE-791 is under clinical development by Contineum Therapeutics and currently in Phase I for Neuroinflammation. According to GlobalData, Phase I...